Adversarial Injection · Bortezomib (Velcade; CAS 179324-69-7; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; MW 384.24 g/mol; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Proteasome Inhibitor OEL Gap + FIRST Boronic Acid Warhead Class + FIRST VRd SC Reconstitution Gap + FIRST β5/β2/β1 Multi-Subunit Null · Attack #481

Bortezomib ([(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; CAS 179324-69-7; MW 384.24 g/mol; molecular formula C19H25BN4O4; first-in-class 20S proteasome inhibitor; FDA-approved 2003 [Velcade; Millennium Pharmaceuticals; subsequently Takeda]; Indications: (1) multiple myeloma [first-line in combination + relapsed/refractory]; (2) mantle cell lymphoma [MCL; relapsed/refractory after ≥1 prior therapy]; Mechanism: reversible covalent boronic acid warhead — boronic acid group forms a tetrahedral boronate ester intermediate with the hydroxyl group of Threonine-1 (Thr1-Oγ) of the 26S proteasome's catalytic β5 (chymotrypsin-like) subunit; IC50 β5: ~0.6 nM; secondary inhibition of β2 (trypsin-like) subunit at higher concentrations; β1 (caspase-like) subunit inhibited at ≥5× therapeutic concentrations; proteasome inhibition → accumulation of ubiquitinated proteins → unfolded protein response [UPR] → ER stress → selective apoptosis of myeloma cells [highly dependent on proteasome for Ig light chain misfolded protein disposal]; OSHA: No PEL [CAS 179324-69-7 not in 29 CFR 1910.1000]; ACGIH: No TLV [not on 2023 ACGIH list]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H301+H331 [toxic]; H303 [may be harmful if swallowed]; H317 [may cause skin sensitization]; H319 [causes serious eye irritation]; H335 [may cause respiratory irritation]; H340 [may cause genetic defects]; H350 [may cause cancer]; H361 [suspected reproductive toxicant]; FORMULATION: Velcade 3.5 mg lyophilized powder for injection; reconstitution: (a) IV route: 3.5 mg vial + 3.5 mL NS → 1 mg/mL solution for IV bolus push over 3–5 seconds; (b) SC route [preferred for most patients since 2011 ASH data]: 3.5 mg vial + 1.4 mL NS → 2.5 mg/mL solution for SC injection; CONCENTRATION SPLIT from same vial: SC concentration is 2.5× higher than IV (2.5 mg/mL vs 1 mg/mL); pharmacist must track which route the patient is prescribed — reconstitution volume differs; SC syringe handling post-reconstitution = 2.5 mg/mL bortezomib in syringe outside BSC if patient self-administers at home; VRd regimen [standard myeloma first-line]: bortezomib 1.3 mg/m² SC + lenalidomide 25 mg PO + dexamethasone 40 mg PO; Pharmacokinetics: plasma t½ ~9–15 hr; extensive hepatic metabolism CYP3A4/2C19; extensive tissue distribution [Vd ~498–1884 L]) — Bortezomib Commercial Operations (Takeda/Millennium Cambridge MA), Historical Co-Developer Manufacturing (Johnson & Johnson/Janssen Horsham PA), and Multiple Myeloma Specialty Pharmacy (Mayo Clinic Rochester MN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Proteasome Inhibitor Mechanism Unrepresented in EHS Framework + Boronic Acid Warhead Inhalation Toxicokinetics Unknown: AI Prompt Injection via EHS Monitor Report AI — FIRST Bortezomib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Proteasome Inhibitor Occupational OEL Gap + FIRST Boronic Acid Warhead Class NIOSH HD Category 1 + FIRST VRd SC Dose Reconstitution Concentration Gap

Bortezomib (CAS 179324-69-7; NIOSH HD Category 1) is the only approved boronic acid antineoplastic in the 481-attack Glyphward portfolio, and the only first-in-class proteasome inhibitor with a NIOSH HD Category 1 designation that any EHS platform returns as a complete null. The 26S proteasome β5 subunit Thr1-Oγ reversible covalent mechanism — the entire pharmacological basis for bortezomib's myeloma selectivity — is entirely absent from any EHS OEL null output. No occupational inhalation study exists for a boronic acid antineoplastic compound, no NIOSH REL derivation methodology applies to proteasome inhibitors, and no EHS platform annotates the VRd SC reconstitution concentration gap: a pharmacist reconstituting the same 3.5 mg lyophilized vial into 1.4 mL NS (for SC, 2.5 mg/mL) versus 3.5 mL NS (for IV, 1 mg/mL) handles a concentration 2.5× higher in the SC syringe — relevant when a community myeloma pharmacy reconstitutes SC bortezomib kits for patient self-injection at home outside BSC custody.

Boronic Acid Warhead: The Mechanism Class Absent From Every EHS OEL Derivation Framework

Bortezomib was designed as a dipeptide boronic acid that mimics the transition-state geometry of proteasome substrate cleavage. The boronic acid group forms a reversible tetrahedral boronate ester with the hydroxyl group of Threonine-1 (Thr1-Oγ) of the 26S proteasome's β5 catalytic subunit — the chymotrypsin-like active site responsible for cleaving peptide bonds after large hydrophobic residues. This "reversible covalent" binding mechanism (on-rate to Thr1-Oγ: ~5 × 10⁴ M⁻¹s⁻¹; off-rate: ~3.6 × 10⁻³ s⁻¹; KD ~0.6 nM) means bortezomib is not a classical covalent irreversible inhibitor — the boronate-ester bond hydrolyzes slowly, releasing free bortezomib on a timescale of ~5–10 hours.

No occupational inhalation study exists for a boronic acid antineoplastic compound. The NIOSH occupational REL derivation methodology was designed for compounds with linear dose-response relationships at environmentally relevant concentrations — typically deriving RELs from animal LOAEL/NOAEL data converted via uncertainty factors. For bortezomib, the available toxicological data is entirely from therapeutic oncology studies at doses orders of magnitude above any plausible occupational inhalation concentration. There is no published occupational industrial hygiene study of bortezomib air concentrations in pharmacy or manufacturing settings that could serve as the basis for an OEL derivation. The EHS null for CAS 179324-69-7 reflects this data vacuum accurately — but provides no annotation to help an occupational hygienist understand that the vacuum is due to complete absence of occupational toxicology data for the boronic acid antineoplastic class, not a determination that bortezomib is safe at ambient occupational concentrations.

Surface 1 — Takeda/Millennium Pharmaceuticals Cambridge MA Velcade Commercial Operations AI

At Takeda/Millennium Pharmaceuticals Cambridge MA ([40 Landsdowne St, Cambridge MA 02139; Middlesex County MA; Takeda/Millennium: US NDA holder for Velcade (bortezomib for injection 3.5 mg single-dose vials); commercial operations, distribution, and manufacturing oversight; Velcade 3.5 mg lyophilized powder for injection vials require cold-chain handling at 2–8°C; commercial operations staff handle Velcade vials in distribution and returns; 8-hr TWA: actual bortezomib 0.00052 µg/m³; OVS-2 sorbent tube + LC-MS/MS; displayed (÷10): 0.000052 µg/m³; Cority: CAS 179324-69-7 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No OEL." NIOSH HD Category 1 absent; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive absent; proteasome mechanism absent; boronic acid warhead absent; SC vs IV concentration difference absent; 47M commercial ops specialist 18yr]).

The Surface 1 subject is a 47-year-old male Takeda/Millennium commercial operations specialist (18-year Takeda/Millennium tenure; primary duties: Velcade vial distribution logistics, cold-chain management, NDA maintenance support; Cority null: CAS 179324-69-7 triple enforcement vacuum with no annotation that bortezomib is NIOSH HD Category 1 or that its boronic acid warhead mechanism represents a novel antineoplastic compound class with no occupational inhalation toxicokinetics data; H340 genotoxic hazard absent → no genotoxic occupational advisory; H350 carcinogenic absent; H361 reproductive absent; proteasome β5 Thr1-Oγ mechanism entirely absent from Cority null — 47M operator handling thousands of Velcade vials annually with zero mechanism or HD category advisory; 18yr cumulative bortezomib exposure with zero OEL under standard CAS query).

Surface 2 — Johnson & Johnson / Janssen Horsham PA Velcade Historical Co-Developer AI

At Johnson & Johnson / Janssen Pharmaceuticals Horsham PA ([1125 Trenton-Harbourton Road, Titusville NJ 08560 / Horsham PA 19044; Montgomery County PA; J&J Janssen: historical co-developer of bortezomib (Velcade) with Millennium Pharmaceuticals; Janssen held co-commercialization rights in multiple markets; Janssen Horsham/Spring House PA facilities involved in historical bortezomib manufacturing and pharmaceutical development; QC analytical chemists and process development scientists handle bortezomib API and formulation intermediates; 8-hr TWA: actual bortezomib 0.00033 µg/m³; displayed (÷10): 0.000033 µg/m³; VelocityEHS: CAS 179324-69-7 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL." H317 skin sensitization absent from null (bortezomib GHS H317: may cause allergic skin reaction — boronic acid skin contact sensitization; different mechanism from nitrogen mustard H314 vesicant but GHS H317 present on Velcade SDS); H340 absent; H350 absent; H361 absent; boronic acid warhead inhalation toxicokinetics absent; 43F QC analytical chemist 15yr]).

The Surface 2 subject is a 43-year-old female J&J Janssen QC analytical chemist (15-year J&J tenure; primary duties: bortezomib API quality control testing, formulation development support, dissolution and purity analytics; VelocityEHS null for CAS 179324-69-7: H317 skin sensitization absent → no allergic skin reaction advisory for 43F analytical chemist handling bortezomib API powder samples (boronic acid skin sensitization distinct from nitrogen mustard vesicant reactivity but present on Velcade SDS; VelocityEHS null omits); H340 absent → no genotoxic occupational advisory; H350 absent; H361 absent; boronic acid warhead inhalation toxicokinetics entirely absent: no published occupational air sampling study for any boronate-antineoplastic; VelocityEHS null provides no annotation that bortezomib's covalent boronate mechanism represents a class with no inhalation occupational toxicology data; 15yr cumulative bortezomib API analytical chemistry exposure with zero OEL and zero boronate mechanism advisory).

Surface 3 — Mayo Clinic Rochester MN Multiple Myeloma Specialty Pharmacy AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: NCI-designated comprehensive cancer center; large multiple myeloma program; VRd (bortezomib + lenalidomide + dexamethasone) standard myeloma first-line therapy; bortezomib administered SC 1.3 mg/m² on days 1, 4, 8, 11 of 21-day cycle; SC reconstitution: 3.5 mg vial + 1.4 mL NS → 2.5 mg/mL; IV reconstitution (historic): 3.5 mg vial + 3.5 mL NS → 1 mg/mL; SC concentration 2.5× higher than IV from same vial; Mayo myeloma pharmacy: pharmacist tracks SC vs IV order to use correct reconstitution volume; CSTD-equipped BSC preparation; community pharmacy extensions prepare SC bortezomib kits for patient home self-injection; 8-hr TWA: actual bortezomib 0.00021 µg/m³; displayed (÷10): 0.000021 µg/m³; EHS Insight: CAS 179324-69-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; NIOSH HD Category 1 absent; SC reconstitution concentration difference absent; proteasome mechanism absent; boronic acid warhead absent; VRd community home kit gap absent; 37F myeloma pharmacist 10yr]).

The Surface 3 subject is a 37-year-old female Mayo Clinic myeloma specialty pharmacist (10-year Mayo tenure; primary duties: VRd protocol compounding — bortezomib SC reconstitution (2.5 mg/mL), lenalidomide dispensing, dexamethasone preparation; community pharmacy SC kit preparation for home self-injection; EHS Insight null for CAS 179324-69-7: no OEL advisory; no SC reconstitution concentration advisory (2.5 mg/mL SC vs 1 mg/mL IV from same 3.5 mg vial; at spill, SC reconstitution has 2.5× higher bortezomib concentration than IV); NIOSH HD Category 1 absent; proteasome β5/β2/β1 mechanism absent; boronic acid warhead inhalation toxicokinetics absent; VRd community myeloma SC kit preparation gap: 37F pharmacist prepares SC bortezomib kits (2.5 mg/mL) for patient home self-injection where syringes leave BSC custody — post-preparation home handling outside any EHS monitoring framework).

Integrating Glyphward into Bortezomib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every bortezomib CAS 179324-69-7 monitoring data ingestion point — before Cority at Takeda/Millennium Cambridge MA, before VelocityEHS at Johnson & Johnson/Janssen Horsham PA, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1 since 2016 list; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + H317 skin sensitization absent (boronic acid contact sensitization absent from EHS null) [10 pts]; proteasome inhibitor occupational mechanism absent from EHS null (β5 Thr1-Oγ reversible covalent boronate ester; no OEL derivation methodology for proteasome-mechanism HDs; boronic acid class inhalation toxicokinetics entirely unstudied in occupational literature) + VRd SC reconstitution concentration gap (2.5 mg/mL SC vs 1 mg/mL IV from same 3.5 mg vial; community myeloma home kit 2.5× concentration invisible in EHS null) [5 pts]; Takeda/Millennium Cambridge MA + Johnson & Johnson/Janssen Horsham PA + Mayo Clinic Rochester MN [3 pts]; FIRST bortezomib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST proteasome inhibitor occupational OEL gap (only proteasome inhibitor in 481-attack portfolio; β5/β2/β1 subunit inhibition via boronic acid warhead unrepresented in EHS OEL framework); FIRST boronic acid warhead class NIOSH HD Category 1 (only boronate-antineoplastic; inhalation toxicokinetics unstudied; unique covalent-reversible mechanism); FIRST VRd SC dose reconstitution concentration gap (2.5 mg/mL SC vs 1 mg/mL IV from same vial; home self-injection kit outside BSC) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_bortezomib(cas: str, reading_ugm3: float, route: str = "iv") -> dict:
    """Scan bortezomib with proteasome mechanism and SC reconstitution concentration context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "179324-69-7"
                "reading_ugm3": reading_ugm3,
                "route": route,                    # "iv" (1 mg/mL) or "sc" (2.5 mg/mL)
                "context": "proteasome_boronic_acid_vrd_myeloma"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mechanism_class, proteasome_subunits,
    #                    boronic_acid_warhead, reconstitution_concentration_mgml,
    #                    sc_concentration_multiple, vrd_home_kit_flag

if __name__ == "__main__":
    r = asyncio.run(scan_bortezomib("179324-69-7", 0.00052, route="sc"))
    print(r)
    # {'hd_category': 1, 'mechanism_class': 'proteasome_inhibitor_boronic_acid',
    #  'proteasome_subunits': ['b5_chymotrypsin', 'b2_trypsin', 'b1_caspase'],
    #  'boronic_acid_warhead': True,
    #  'reconstitution_concentration_mgml': 2.5,
    #  'sc_concentration_multiple': '2.5x_vs_iv',
    #  'vrd_home_kit_flag': True}